NDATRANSDERMALSYSTEM
Approved
Oct 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
CATAPRES-TTS-2 (clonidine transdermal system) by Lavipharm is adrenergic alpha2-agonists [moa]. Approved for central alpha-2 adrenergic agonist [epc]. First approved in 1984.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CATAPRES-TTS-2 is a transdermal clonidine system approved in 1984 that delivers the central alpha-2 adrenergic agonist clonidine across the skin for systemic antihypertensive effect. It is indicated for hypertension management and works by stimulating alpha-2 adrenergic receptors in the central nervous system to reduce sympathetic outflow and lower blood pressure.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), signaling potential team consolidation and shift toward generic or life-cycle management strategies.
Mechanism of Action
Adrenergic alpha2-Agonists
Pharmacologic Class:
Central alpha-2 Adrenergic Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CATAPRES-TTS-2 offers limited career growth in innovation but strong opportunity to develop expertise in mature product management, generic competition strategy, and market transition execution. This role suits professionals seeking defensive commercial experience and lifecycle management credentials in a stable but declining franchise.
Brand Manager
Worked on CATAPRES-TTS-2 at Lavipharm? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.